Introduction
Ovarian cancer generally does not exhibit specific early symptoms. About 60% of ovarian cancers are diagnosed at late stage, which is associated with a 5-year survival of less than 30%, contrasted with more than 90% survival for disease found locally (1) . This has prompted extensive research to find early detection biomarkers for ovarian cancer.
Many potential serum biomarkers for ovarian cancer have been indentified (2) . Candidate biomarkers are often first identified from preclinical studies using immunohistochemical testing or gene expression profiles of tumor tissue. These are called Phase I studies (3) . Potential biomarkers are then tested by comparing blood from cases at diagnosis of ovarian cancer with blood from either women with benign disease or healthy controls. This type of study has been described as a Phase II study. Markers that have been approved using Phase II data include CA125, HE4, and a panel of markers, including prealbumin, apolipoprotein A-1, β 2 -microglobulin, and transferrin (4, 5) . CA125 has been approved for disease monitoring (6) , and HE4 and a panel of markers as tools for distinguishing benign from malignant pelvic masses (4, 5) . Phase III data refers to studies based on blood samples from asymptomatic women taken months or years prior to a diagnosis of ovarian cancer, while phase IV data refers to markers tested in a clinical trial in which asymptomatic women are randomized to a screening arm or to usual care.
There have been three randomized trials of screening for ovarian cancer using either CA125 alone or CA125 in combination with transvaginal ultrasound (TVUS). No reduction in ovarian cancer mortality was observed in the Prostate, Lung, Colorectal, and Ovarian cancer (PLCO) screening trial, based on a combination of TVUS and CA125 measurements for four years and two additional years of CA125 measurements (7) . However, recent results from the UKCTOCs study showed a 15% reduction in mortality for postmenopausal women followed for change in CA125, which was marginally significant (8) . One additional randomized trial in Japan (9) Research.
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Although selected specimens from the Phase IV studies may be and have been used in the context of discovering and testing new biomarkers, they may not be ideal for this purpose for at least two reasons. First, since CA125 was the primary screening tool, this may lead to preferential selection of CA125-expressing tumors. Second, since annual screening was employed, the natural history of the disease may have been interrupted at early stages and may not provide a true measure of the lead time, i.e. the time between early diagnosis with screening and when diagnosis would have occurred in the absence of screening. Therefore, samples collected in asymptomatic women before cancer diagnosis are needed to test new biomarkers.
To date, only a few case-control comparisons have been made in prospectively collected specimens obtained in asymptomatic women before clinical cancer diagnosis under usual care (Phase III studies) (10) (11) (12) . Both the Carotene and Retinol Efficacy Trial (CARET) and Women's Health Initiative (WHI) studies were designed as randomized trials to evaluate other disease outcomes but have the advantage of closely monitoring a large group of women with banked blood samples. In the CARET study, a panel of markers including CA125, HE4, mesothelin, B7-H4, DcR3, and spondin-2 were measured on serial samples from 34 women with ovarian cancer and 70 matched controls. Of these, only CA125 and HE4 showed significant differences between cases and controls and had modest discriminatory ability that waned with increasing time between blood draw and diagnosis. Similarly in the WHI study, CA125 and HE4 were measured in 353 ovarian cancer cases and 1,261 healthy controls and these markers significantly improved a risk prediction algorithm based on epidemiologic factors (11) .
Here, we present results from a Phase III study using serum samples from the EPIC cohort (European Prospective Investigation into Cancer and Nutrition). We measured CA125, CA15.3, HE4 and CA72.4 in 197 cases of ovarian cancer diagnosed within the first three years after blood donation and 724 matched control subjects. For 613 additional ovarian cancer patients diagnosed more than 3 years after blood draw, and for 1,215 additional control subjects, we extended the measurements of CA125 and CA15.3 for examination of a possible longer-term risk diagnostic prediction capacity of these markers and to allow more accurate analyses of possible relationships of these markers with epidemiologic risk factors for ovarian cancer. The objectives of our analyses were: (i), to examine the early detection capacity of our biomarker panel for ovarian cancer diagnoses within comparatively short time intervals (variable lag time strata ≤3 years between blood donation and diagnosis); (ii), to examine the capacity of CA125 and CA15.3 to predict ovarian cancer risk over a longer term (>3 years between blood donation and diagnosis); and (iii), to examine whether early diagnostic capacity or longer-term risk prediction by the biomarkers could be improved by integrating further information about a woman's general epidemiologic risk factor profile.
Research. 
Materials and Methods

The EPIC cohort -background and collection of blood samples
The European Prospective Investigation into Cancer and Nutrition is an ongoing multicenter prospective cohort study designed to investigate the relationship between diet, nutrition and metabolic factors with cancer. Descriptions of study design, population and baseline data collection of the cohort have been reported in detail previously (13, 14) . In brief, 519,978 participants (366,521 women) were enrolled from 1992 to 2000 in 23 centers in 10 European countries: Denmark, France, Germany, Greece, Italy, Norway, the Netherlands, Spain, Sweden, and the United Kingdom. For women, the age range at recruitment was mostly between 35 to 70 years. At baseline, comprehensive data on diet, lifestyle, reproductive and menstrual factors, current and past use of exogenous hormones (oral contraceptives [OC] and postmenopausal hormone replacement therapy [HRT] ) and medical history were collected through standardized questionnaires. In addition, anthropometric measures were obtained.
A total of 385,747 study participants in the EPIC cohort (226,673 women and 159,074 men) also provided a baseline blood sample. In France, the Netherlands, the United Kingdom, Germany, Spain, Italy and Greece blood samples were collected according to a standardized protocol (15) . From each study participant, about 30 ml of blood were drawn, and serum, plasma, erythrocytes and buffy coat were aliquoted in 28 plastic straws of 0.5 ml each, which were heatsealed and stored under liquid nitrogen (-196ºC) . In Denmark, blood fractions were aliquoted into 1-ml tubes, and stored in the vapor phase in liquid nitrogen containers (-150ºC). In the Swedish Center of Umeå, blood samples were divided into 10 aliquots of 1.5-mL each: 6 plasma, 2 buffy-coat and 2 erythrocytes, which were rapidly frozen at -80ºC in standard freezers.
Ascertainment of incident cancer cases
Prospective follow-up for cancer occurrences and histologic confirmation was performed through record linkage with cancer and pathology registries (all countries except France, Germany and Greece) or through active follow-up and systematic verification of self-reports by detailed examination and coding of clinical records. In all countries, vital status was determined by regular linkages with population and mortality registers at the regional or national level. 
Design of nested case-control study
For each case subject up to four control subjects were randomly selected among appropriate risk sets consisting of all female cohort members with a blood sample, alive and free of cancer at the time of diagnosis of the index case. An incidence density sampling protocol was used, such that, in principle, control subjects could include study participants who became a case later in time and each control subject could be sampled more than once -the control subjects actually drawn, however, did not include any of the future cases of ovarian cancer detected so far in the EPIC cohort. Case and control subjects were matched on study recruitment center, age at blood donation (±6 months), time of the day of blood collection (±1 h), fasting status (<3 h, 3-6 h, >6 h), follow-up time, and menopausal status at blood collection (premenopausal, perimenopausal, postmenopausal), current use of exogenous hormones (oral contraceptives, HRT) at the time of blood draw, as well as menstrual cycle phase for premenopausal women (3-5 categories, depending on available data). Cases missing data on phase of menstrual cycle were matched to control subjects whose information on menstrual cycle phase was also missing.
Informed consent and data protection
All participants had given their consent for future analyses of their blood samples and the duplex, and they were tested at a 50-fold dilution in the CA15.3 assay. A quality control pool was prepared from serum samples from ovarian cancer patients with within linearity range levels of each protein and split into equal aliquots. To establish inter-plate variability, one aliquot of this pool was tested at multiple dilutions spanning the linearity range of each assay, three dilutions run in duplicates and two dilutions run in triplicates, providing up to six quality control data points in each assay plate. In addition, blinded, randomly chosen citrated plasma, EDTA for CA125, 22% and 3-5% (4%) for CA15.3, 9% and 4-10% (6%) for HE4, 16% and 1-16% (6%) for CA72.4. Since the majority of the blinded aliquots for CA72.4 fell below the lower limit of detection, blinded CA72.4 CVs were based on the remaining 13 aliquots, ranging in CA72.4 value from 1.15 to 1.87 U/mL.
Statistical analyses
First, we evaluated the distribution of each biomarker for normality and outliers. As 81% of the samples had CA72.4 values below the lower limit of detection for this assay (1.119 U/mL), we assigned these values to the midpoint between zero and the lower limit of detection for future analyses. Other markers assessed did not have any values below the lower limit of detection.
Locally estimated scatterplot smoothing (LOESS) curves were used to describe mean levels of each marker among cancer cases and control subjects at different lag-times until ovarian cancer diagnosis. The discrimination between cases and control subjects was described using receiver operating characteristic (ROC) curves, with the area under curve, also known as the C-(concordance) statistic, as an overall measure for discrimination capacity. We estimated the diagnostic sensitivities (SE95 and SE98, respectively) of each marker at cut-points corresponding to 95% and 98% specificity, determined in our full dataset for all control subjects (N = 1,939 for CA125 and CA15.3; N= 725 for HE4 and CA72.4).
The diagnostic sensitivity, specificity and C-statistics were calculated for risk scores based on the associations between biomarker levels and ovarian cancer risk, overall and by strata of lagtime between blood donation and cancer diagnosis, conditional logistic regression models were used, accounting for the matched study design. Models were fitted for continuous biomarker measurements after log 2 -transformation, to achieve approximate normality of their distributions.
Basic analyses focused on single markers. Additional multivariate models were developed to examine the discrimination capacity of multiple markers in combination, and of markers combined with an epidemiologic risk prediction algorithm, including age at menopause, duration of hormone replacement therapy, body mass index, unilateral ovariectomy, duration of oral contraceptive use, and number of full-term pregnancies that we developed previously on the basis of the full EPIC cohort data (16) .
To examine how the early detection and/or risk prediction capacities of the biomarkers changed with time between blood draw and clinical cancer diagnosis, all analyses were performed within variable strata of lag-time (≤6 months, ≤12 months, 1-2 years, 2-3 years, 3-6 years, >6 years).
To examine heterogeneity of diagnostic prediction capacity by tumor stage at diagnosis or by histologic tumor sub-types, likelihood-ratio tests were used comparing the model fit for logistic regression models with and without corresponding interaction terms. For all risk models, the discrimination between cases and control subjects was described using ROC curves.
For multi-marker discrimination models, the statistical fit of nested models was compared with likelihood-ratio tests, and bootstrapping methods were used to correct for model overfitting and over-optimism in the estimation of discrimination capacity. Additionally, measures of continuous net reclassification improvement were calculated, which represents the percent of case and control subjects correctly re-classified as a result of the added marker (17) . Analyses were conducted in SAS (version 9.3, SAS Institute, Cary, NC, USA).
Results
Baseline characteristics of ovarian cancer case patients by tumor characteristics are presented in Table 1 . Of the 810 case patients examined in this study, 752 (93%) had the ovary classified as primary tumor site, whereas in 33 (4%) the primary site was the fallopian tube and in 25 patients (3%) it was the peritoneum. More than half of the tumors (55%) were of serous histology (n = 445), 12% endometrioid (n = 96), 7% mucinous (n = 58), 5% other (malignant Supplementary Table   S1 ). Overall, the median age at cancer diagnosis was 62.7 years (range: 30.6 -86.5 years), and varied according to the histologic subtypes (Supplementary Table S1 ).
Visual inspection of locally estimated scatterplot smoothing (LOESS) curves suggests that none of the biomarkers were increased over normal (control) values earlier than about two years prior to diagnosis, and more than 6 months prior to diagnosis increased levels were discernable only for case patients who were diagnosed with ovarian cancer at advanced stage (stage II or III) (Figure 1) .
For the pre-defined variable lag times between blood donation and date of diagnosis, the ability of the early detection markers to discriminate between case patients and control subjects is indicated by C-statistics and estimated sensitivities at specificity cut-points of 95% (SE95) and 98% (SE98) ( Table 2 ). In addition, receiver operator characteristic (ROC) curves are shown in Table 2) .
Within the first 12 months after blood donation, for all markers except CA15.3 the ability to predict future cancer diagnosis was clearly stronger for advanced tumors (stage II and III/IV) and relatively weak for stage I tumors (Supplementary Figure 1) , and this heterogeneity was statistically significant for CA125 and HE4 (p het < 0.05; Table 2 ). Regarding tumor histology, CA125, HE4 and CA72.4 showed fairly strong discrimination of serous ovarian cancer patients from their matched controls, especially within short lag-times after blood donation (Supplementary Table S2) ; for the other histologic subtypes, the numbers of patients were too small to obtain reliable estimates.
Among the control subjects, no meaningful correlations between markers were observed (r = -0.15 to 0.18). Among the case subjects only, and especially among those with lag-times since blood donation below 1 or 2 years, moderately strong correlations were observed between CA125, HE4 and CA72.4 (e.g., within 1-year's lag-time: r = 0.23 to 0.74), whereas CA15.3
showed somewhat weaker associations with the other markers (within 1-year's lag-time: r = 0.11 to 0.24) (Supplementary Table S3) .
In a stepwise forward selection strategy, focusing on variable lag-time strata within the first 3 years after blood donation, the overall model fit for a logistic risk model improved statistically significantly with successive additions of CA125, HE4, CA72.4 and CA15.3 as pre-diagnostic predictors of future ovarian cancer diagnosis, although the statistical significance for CA15.3 was lowest and largely restricted to lag-times less than 6 months ( Table 3) . However, the overall improvements in the overall discrimination, assessed by C-statistic ( Table S4 ), were small compared to a model based on any of the markers CA125, HE4 or CA72.4 alone.
Finally, we examined whether the overall discrimination between case patients and control subjects could be improved by combining the biomarkers with an epidemiologic stratification algorithm that was developed previously using the full EPIC cohort data (16) . Because some of the key epidemiologic risk variables included in the algorithm (age, menopausal status, use of oral contraceptives or hormone replacement therapy [HRT]), overlapped with some of the matching factors for the present nested case-control study, the risk model showed a lower discrimination (C = 0.56) in our case-control set as compared to our previous full cohort analysis (corrected for over-optimism, C = 0.64). For lag-times below 2 years, combining the risk model with the biomarkers did not improve overall discrimination as compared to each of the biomarkers alone (results not shown). By contrast, for lag times greater than 3 years, the longerterm prediction of future ovarian cancer diagnosis was moderately but significantly improved when CA125 was added to the model (C=0.57 vs. C=0.55), whereas adding CA15.3 showed no improvement.
Discussion
In our evaluation of four potential ovarian cancer screening biomarkers measured in prospectively collected samples from women with ovarian cancer and matched controls in the EPIC cohort, we observed the best sensitivity and specificity for CA125, followed by HE4, CA72.4, and finally CA15.3. The ability of these biomarkers to distinguish cases from controls declined with increasing time between blood draw and diagnosis, as well as with earlier stage at diagnosis. These observations suggest that, generally, these markers are best at identifying advanced disease close to diagnosis, but their ability to detect early disease that is amenable to interventions that can improve survival may be limited. Addition of a previously established risk prediction model did not improve the performance of markers in women who went on to develop clinically manifest ovarian cancer less than three years in advance of diagnosis. By contrast, adding CA125 (but not CA15.3) to the risk prediction model did slightly improve the longer-term prediction of ovarian cancer occurrence over a time interval of about 3 to 6 years after blood donation.
Our results are consistent with those from large randomized trials and prospective assessments of these markers in other populations. All four of these biomarkers were included in an ancillary study of 49 biomarkers previously evaluated in Phase II studies, and all four were also among the best 35 that were subsequently examined within the prospective PLCO cohort (18) . Results from the PLCO study were similar to what we observed in EPIC, with the best performance in cases diagnosed six months or less after blood draw (depending on the time between blood draw and diagnosis), C-statistics ranged from 0.83-0.96 for CA125, 0.78-0.88 for HE4, 0.80 for CA72.4, and 0.72 for CA15.3. As in our present study, the discriminatory ability of these markers in the PLCO cohort declined rapidly for samples collected more than six months prior to diagnosis. An important difference between PLCO and our study, however, is that PLCO participants had been annually screened for ovarian cancer by CA125 plus ultrasonography, Despite having the best performance among various candidate markers considered for ovarian cancer screening in various studies (10, 18, 19) , annual CA125 measurement (combined with transvaginal ultrasound) in the PLCO randomized trial showed no mortality benefit (7) . This lack (22) . Furthermore, recent mortality results from the UKCTOCs revealed a 15% reduction in mortality for women screened using the ROCA algorithm among incident cases (p=0.02) (8) .
Results from various Phase II and other clinical studies have suggested that combinations of multiple biomarkers may be better at distinguishing malignant from benign tumors than CA125 alone. For example, improved discrimination has been documented for the combination of CA125 and HE4 -the two strongest discriminating biomarkers in our analyses -as compared either marker alone (12, (24) (25) (26) (27) (28) (29) (30) (31) . While our analyses confirm that biomarker combinations improve prediction of future ovarian cancer diagnosis, the absolute gain in classification appeared to be small in our data, and a similar observation was made in the PLCO cohort (19) .
Thus, the addition of biomarkers can improve the discriminatory ability of CA125 but current biomarkers may not improve performance to the degree required for population screening.
Analyses in the PLCO study as well as ours, show substantial discrepancy between the often promising findings from Phase-II discovery studies based on clinical case-control comparisons and their lack of replication in prospective evaluations based on pre-diagnostic blood samples.
This observation has triggered recommendations that greater care should be taken in selecting the appropriate sample set for screening biomarker discovery. In particular, it was recommended that prospective cohort studies should be used for new biomarker discovery rather than simply validation of known candidate biomarkers (32-34). One advantage of such an approach would be that it ensures rigorous internal validity for the evaluation of systematic differences between case and control subjects. Another possible advantage of the prospective design is that, by focusing on blood samples collected months prior to cancer diagnosis, one would avoid a bias towards markers exclusively associated with advanced disease (32) . While attractive from a methodological perspective, however, the use of prospective cohorts for biomarker discovery may have several limitations in practice. In our study, among 366,521 women mostly aged 35-70 at blood donation, there was an annual incidence of about 35 ovarian cancer cases. Thus, assuming an early detection time window of 6-18 months prior to diagnosis (excluding the first 6 months of follow-up to reduce the presence of advanced disease), studies for marker discovery would be based on a very limited, yet etiologically diverse sample set. This basic observation illustrates that even very large prospective cohorts may not have a sufficient number of cases for biomarker discovery studies focusing on early stage disease. Moreover, as already noted, the tumor grade and stage at the time of blood sampling would remain unknown. Therefore, uncertainty will remain as to whether those patients whose tumor would have had elevated biomarkers 6-18 months prior to diagnosis (and hence potentially detected) would actually benefit from detection at that timepoint. In light of these limitations, we believe that, as a complement to prospective cohort studies, bio-banking initiatives in large clinical networks will remain needed for the collection of samples especially from well-characterized early-stage patients to allow large-scale comparisons with samples from cancer-free individuals.
In summary, CA125 and HE4 continue to hold potential for ovarian cancer screening but lack sensitivity and specificity needed to detect early stage disease. New biorepositories of early stage disease and matched controls are needed to identify novel markers that focus on the 
disease timepoint where intervention can make the biggest improvement in mortality and morbidity.
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